Servier India introduces ‘Ivosidenib’ (Tibsovo®),in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
You are now leaving the Servier India website
Servier India is not responsible for content on third party websites. Do you wish to continue?